Display options
Cite
Okuma K, Yamashita H, Kobayashi R, et al. A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer. J Contemp Brachytherapy. 2015;7(2):128-34doi: 10.5114/jcb.2015.50720.
Okuma, K., Yamashita, H., Kobayashi, R., & Nakagawa, K. (2015). A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer. Journal of contemporary brachytherapy, 7(2), 128-34. https://doi.org/10.5114/jcb.2015.50720
Okuma, Kae, et al. "A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer." Journal of contemporary brachytherapy vol. 7,2 (2015): 128-34. doi: https://doi.org/10.5114/jcb.2015.50720
Okuma K, Yamashita H, Kobayashi R, Nakagawa K. A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer. J Contemp Brachytherapy. 2015 Apr;7(2):128-34. doi: 10.5114/jcb.2015.50720. Epub 2015 Apr 09. PMID: 26034493; PMCID: PMC4444455.
Copy Download .nbib Format: NLM
Share it on

J Contemp Brachytherapy. 2015 Apr;7(2):128-34. doi: 10.5114/jcb.2015.50720. Epub 2015 Apr 09.

A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer.

Journal of contemporary brachytherapy

Kae Okuma, Hideomi Yamashita, Reiko Kobayashi, Keiichi Nakagawa

Affiliations

  1. Department of Radiation Oncology, The University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo, Japan.

PMID: 26034493 PMCID: PMC4444455 DOI: 10.5114/jcb.2015.50720

Abstract

PURPOSE: This study assessed the trial of boost intracavitary brachytherapy (ICBT) for the patients of uterine cervical cancer with residual malignant cells detected at the final stage of ICBT.

MATERIAL AND METHODS: This is a retrospective analysis of 75 patients with cervical cancer treated radically with external beam radiotherapy and high-dose-rate intracavitary brachytherapy between August 2004 and December 2008. Eighteen patients (24%) out of 75 received one additional ICBT and five patients (7%) had two additional ICBT. All 75 patients were retrospectively analyzed. The median follow-up time was 30 months. The median age was 59 years (range 28-85 years). There were 12 patients (16%) in stage IB, 27 (36%) stage II, 22 (29%) stage III, and 14 (19%) stage IV.

RESULTS: The 5-year overall survival rate was 65%. Non-hematological toxicities greater than grade 2 occurred in 12 patients (16%). Of these, only two patients received on additional ICBT. No significant difference was found in grade 3 toxicity between patients who did and did not receive additional ICBT (p = 0.8).

CONCLUSIONS: The method to perform dose escalation should be examined depending on the treatment response.

Keywords: cervical cancer; high-dose-rate brachytherapy; radiation therapy; toxicity

References

  1. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11 - PubMed
  2. Radiother Oncol. 2007 May;83(2):148-55 - PubMed
  3. Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):33-48 - PubMed
  4. J Clin Oncol. 1999 May;17(5):1339-48 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):83-90 - PubMed
  6. Radiother Oncol. 2006 Jan;78(1):67-77 - PubMed
  7. N Engl J Med. 1999 Apr 15;340(15):1137-43 - PubMed
  8. N Engl J Med. 1999 Apr 15;340(15):1144-53 - PubMed
  9. Int J Gynecol Cancer. 2012 Oct;22(8):1420-6 - PubMed
  10. Radiother Oncol. 2005 Mar;74(3):235-45 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1506-13 - PubMed
  12. Lancet. 1997 Aug 23;350(9077):535-40 - PubMed
  13. Radiother Oncol. 2011 Jul;100(1):116-23 - PubMed

Publication Types